STAT Plus: Relay Therapeutics, focused on solid tumors, seeks to raise $250M in IPO
Relay Therapeutics, a Cambridge, Mass.-biotech focusing on cancer treatments, plans to raise $250 million when…
Category: biotechnology
STAT Plus: A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it
CytoDyn is nearing the completion of a clinical trial investigating the use of leronlimab, its…
.jpg)
STAT Plus: With a clinical hold, off-the-shelf CAR-T hits a new safety concern
The Food and Drug Administration has placed a clinical hold on one of Cellectis’s off-the-shelf…
STAT Plus: Venter Institute, Yumanity, and other biopharma companies among recipients of PPP loans
Yumanity, the J. Craig Venter Institute, and dozens of other companies around the biotech industry…
STAT Plus: Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial
Immunomedics reported clinical trial results Monday showing its newly approved medicine, Trodelvy, reduced the risk…
STAT Plus: Bellus Health suffers setback with clinical trial failure of chronic cough drug
Bellus Health is reporting Monday negative results from a mid-stage clinical trial of its experimental…
Trial of Moderna Covid-19 vaccine delayed, investigators say, but July start still possible
A 30,000-patient trial of Moderna’s coronavirus vaccine candidate, expected to start next week, has been…
.jpg)
Inovio claims positive results on Covid-19 vaccine but critical data are missing
Inovio Pharmaceuticals on Tuesday said that its investigational Covid-19 vaccine had “positive” results in a…
STAT Plus: The biotech scorecard for the third quarter: 14 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT Plus: How Gilead’s remdesivir price could come back to haunt the drug industry
Gilead Sciences, in a self-described effort to do “the right and responsible thing,” may have…
STAT Plus: FDA rejects Intercept Pharma’s drug for NASH
Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat…
Two patients die in Audentes gene therapy study, heightening concerns over high-dose treatments
Two patients in a study of a high-dose gene therapy for a rare muscle disorder…
STAT Plus: Zogenix wins approval for new drug to treat rare type of childhood epilepsy
A new drug from Zogenix that treats a rare and severe type of epilepsy was…
STAT Plus: Federal prosecutors allege Regeneron used a charity to pay kickbacks to Medicare patients
Federal officials on Wednesday alleged that Regeneron Pharmaceuticals (REGN) donated tens of millions of dollars…
STAT Plus: Yumanity Therapeutics, Merck strike deal aimed at developing new medicines for neurodegenerative disease
Yumanity Therapeutics, a small neuroscience-focused startup co-founded by longtime biotech executive Tony Coles, is pairing…
STAT Plus: As approval decision nears, fate of Intercept’s NASH drug clouded by murky FDA review delays
On Friday, the Food and Drug Administration is supposed to announce its decision on whether…
STAT Plus: Sana Biotechnology, the secretive startup, lays (some) cards on the table
After years of rumors, Sana Biotechnology is officially biotech’s newest unicorn. The company announced Tuesday…
STAT Plus: A Chinese drug maker scores a big clinical trial win with a novel diabetes therapy
Two years ago, Hua Medicine turned to the public markets to help finance its ambitious…
STAT Plus: A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know
Bellus Health, a small Canadian drug maker, is seeking to develop a potential blockbuster medicine…
STAT Plus: Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug
Shares of Biogen fell Thursday after a federal court judge ruled in favor of generic…
STAT Plus: CAR-T cells, better known as cancer drugs, show promise against aging in lab mice
Scientists are still trying to get CAR-T cells to work as well in solid tumors…
STAT Plus: Eli Lilly gets an edge against Pfizer in adjuvant breast cancer
Eli Lilly announced Tuesday that adding its drug Verzeneio to hormone blockers decreased the risk…
STAT Plus: Momenta Pharma drug improves symptoms in patients with myasthenia gravis
Momenta Pharmaceuticals reported Monday that in a mid-stage clinical trial, an experimental medicine significantly improved…
STAT Plus: What’s at stake for industry in the pharmaceutical Space Race for a Covid-19 vaccine
The Trump administration’s move to pick five companies as finalists in the quest to develop…
Sinovac says early data show its Covid-19 vaccine generated immune responses
Sinovac Biotech announced preliminary study results on Saturday showing its experimental Covid-19 vaccine generated immune…
STAT Plus: As efficacy of Constellation’s blood cancer drug wanes, the debate over its future ratchets higher
The response rate to an experimental myelofibrosis drug is falling, Constellation Pharmaceuticals, the drug’s maker,…
STAT Plus: Agios drug demonstrates strong response in patients with inherited blood disorder
Agios Pharmaceuticals on Friday reported positive results from the first clinical trial of its lead…
STAT Plus: New data in sickle cell show biotech companies tackling disease in novel ways
Sickle cell disease features prominently at this year’s virtual meeting of the European Hematology Association,…
One of biotech’s biggest conferences grapples with how to talk about race and identity
If you’re trying to explain systemic racism to a group of scientists and biotech professionals,…
The Chan-Zuck uprising, a virtual BIO, and the struggle to treat Covid-19
Can a virtual conference feel real? Do scientists have a say in their benefactors’ business?…
STAT Plus: Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease
Verve Therapeutics, a Cambridge biotech that wants to use gene-editing to lower cholesterol, said Thursday…
Opinion: What being stricken with Covid-19 taught a biotech CEO
On March 14, at 10 a.m., I got the call that I had tested positive…
Opinion: A pandemic, a funeral, and a chance to help heal the world
At the J.P. Morgan Healthcare Conference for biotech investors in San Francisco this January, I…
STAT Plus: ‘An extremely volatile time’: New report underscores the recent rollercoaster of the biotech market
A new report from BIO shows just how chaotic the last few years have been…
STAT Plus: As biotech drifts from amyloid hypothesis for Alzheimers, some see reason to cling on
Two biotech CEOs are cautiously optimistic about the controversial amyloid hypothesis, which suggests a sticky…
STAT Plus: China’s biggest-ever Nasdaq biotech IPO comes at an awkward time
Legend Biotech raised more than $400 million in a Nasdaq IPO on Friday, marking the…
STAT Plus: Startup developing an inhaler for seizures is acquired by UCB
A startup conceived to improve emergency treatment for epileptic seizures based on a father’s fears…
Opinion: Covid-19 is changing the game for health care companies and investors
Even as the health care industry has stepped up with an unprecedented response to the…
Longtime executive Tony Coles on biotech, racism, and opportunities for change
The killing of George Floyd at the hands of a white Minneapolis police officer has…
Listen: The killing of George Floyd, the drug industry’s response, and what comes next
We’re going to do something different on this episode of “The Readout LOUD,” STAT’s biotech…
STAT Plus: In a first for RNA-modifying drugs, AstraZeneca partners with startup Accent Therapeutics
Drug giant AstraZeneca is moving deeper into RNA-based therapies with a new partnership with the…
STAT Plus: Moderna released scant Covid-19 data to prevent a leak, CEO says
The biotech company Moderna invited the scrutiny of the world last month when it withheld…
STAT Plus: Lawmakers, government watchdog blast FDA for poor oversight of U.S. drug supply chain
WASHINGTON — A government watchdog blasted the Food and Drug Administration for fumbling its oversight…
STAT Plus: Innovent starts China’s first trial of a novel cancer immunotherapy
A version of this story appeared Tuesday in STAT China, a weekly guide to biopharma and…
STAT Plus: Pfizer to invest up to $500M in public companies with drugs in the clinic
Pfizer, the world’s largest drug company, is going to try its hand at picking biotech…
STAT Plus: ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress
The annual meeting American Society of Clinical Oncology (ASCO) concluded on Sunday. The closely-followed cancer…
STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
Allogene on Friday released updated results from the first study of its off-the-shelf CAR-T cell…
STAT Plus: AstraZeneca study results could change treatment for certain early-stage lung cancer patients
In April, AstraZeneca halted a clinical trial of its genetically targeted lung cancer drug Tagrisso…
STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it
Q32 Bio has two targets in its sights: the two arms of the immune system….
Opinion: Biopharma companies are spreading misinformation — and taking advantage of it
As Covid-19 upends the world, people are putting their faith in the biopharma industry to…